Inari Medical, Inc. is a medical device company that specializes in developing, manufacturing and commercializing catheter-based technologies for treating venous thromboembolism (“VTE”), a condition that occurs when a blood clot forms in a vein, usually in the lower leg, thigh, or pelvis.

An underlying securities fraud class action complaint alleges that certain officers and directors of Inari consistently touted Inari’s “record revenue,” purportedly driven by “the strength in our core VTE business” while failing to disclose that a significant portion of its expenses were used to compensate medical professionals improperly for using Inari’s products. The Complaint further alleges that the Company was being investigated by the U.S. Department of Justice for unlawfully compensating health care professionals in violation of the federal Anti-Kickback Statute and Civil False Claims Act and had misled investors regarding business expenses in order to conceal their illicit conduct.

Current Inari shareholders who have held shares of the Company’s stock since prior to February 24, 2022 have standing to seek corporate reforms, the return of funds back to company coffers, and potentially receive a court approved incentive award if appropriate.

If you have held Inari shares since prior to February 24, 2022 and would like to learn more about this matter at no cost to you, please us at jgrabar@grabarlaw.com or call 267-507-6085.